A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.

Trial Profile

A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs GSK 732461 (Primary) ; AS01B; AS02
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2011 Primary endpoint 'CD4+-cell-count' has been met
    • 08 Feb 2009 Results were presented at CROI 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top